Share with your friends

Musings on business innovation and the Federal Budget

Musings on business innovation and the Federal Budget

Alan Garcia reflects on the Federal Budget's proposed reductions to the R&D Tax Incentive.

Alan Garcia

Partner, R&D Tax

KPMG Australia


Also on


After three plus years of review, it came as no surprise that the Federal Budget proposed reductions to the Research and Development (R&D) Tax Incentive, Indeed, if the measures are passed unamended, the large majority of current R&D tax claimants will receive less funding.

The proposed measures are:

  • The R&D intensity measure will reduce the net benefit (likely by more than 50 percent) for many existing non-refundables with turnover greater than $20m except for those with an R&D intensity of more than 13 percent. Importantly, due to the blended rates of benefit, if intensity increases from 1 percent to 5 percent, for many companies the average rate of benefit will still be lower than the current 8.5 percent benefit. On the bright side, the budget announcement enables claims of up to $150 million on R&D per year (currently only the first $100 million attracts an additional benefit).
  • For companies with a turnover less than $20 million, the $4 million annual cap was expected but it will not apply to clinical trials. This is a particularly welcome relief for Australia’s globally respected and rapidly growing life sciences industry. Overall, however, smaller companies will receive less funding due to: the proposal to fix the rate of benefit at 13.5 percent as opposed to the current fluctuating benefit of 16 percent; and (for some) as a result of the annual $4 million cap.

Ultimately the Federal Budget is focused on containing the cost of the R&D tax incentive by reducing the tax benefit for most companies and increasing compliance activities. To manage compliance more effectively, we strongly encourage claimants to introduce regular ‘R&D check-ins’ to marry your R&D activities throughout the year to the annual AusIndustry R&D registration. This should link the experimentation and new knowledge gained to the relevant costs incurred on a contemporaneous basis.

Whilst the proposed measures are expected to save more than $2 billion, the Government appears keen to take a more holistic perspective with regard to increasing business expenditure on R&D by reducing company tax rates, strengthening research funding (e.g. $500 million for the Medical Research Future Fund) and improving industry collaboration. The Government hopes that these broader measures will additionally support Australia's economic growth through innovation.

We expect draft R&D legislation to be released for consultation over the next month.

Connect with us


Want to do business with KPMG?


loading image Request for proposal